Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia.

ABSTRACT: Almost two decades ago, the sequencing of the human genome and high throughput technologies came to revolutionize the clinical and therapeutic approaches of patients with complex human diseases. In acute lymphoblastic leukemia (ALL), the most frequent childhood malignancy, these technologies have enabled to characterize the genomic landscape of the disease and have significantly improved the survival rates of ALL patients. Despite this, adverse reactions from treatment such as toxicity, drug resistance and secondary tumors formation are still serious consequences of chemotherapy, and the main obstacles to reduce ALL-related mortality. It is well known that germline variants and somatic mutations in genes involved in drug metabolism impact the efficacy of drugs used in oncohematological dis

SUBMITTER: Barcenas-Lopez DA 

PROVIDER: S-EPMC7720095 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature